French chemists confirm the crisis
The year 2010 had already been an exceptional year, even for groups of historic French chemistry, Rhodia and Arkema. But on Thursday morning, the two companies were again positively surprised markets by announcing strong financial results quarterly.
Alternately, Rhodia and Arkema unveiled a sales growth of 28% for the former and 33% for the second, at 1.77 billion and 1.5 billion euros. On both sides, the Guidelines highlight the sustained increase in volume, about 7% to 9%. In an interview with Le Figaro, Thierry Hénaff, CEO of Arkema, confirms that "the global environment is a carrier for chemists", referring in particular to the dynamism of emerging countries. Yet both groups are very active in high-growth countries.
Historically, Rhodia has developed in Latin America, particularly Brazil, and China.In total, emerging economies account for half its turnover. For his part, Arkema has focused on Asia, especially on China. With 20% of sales in the Asian territory, the group has therefore also a growing market. "In Europe and the United States, we see no sign of abating" moderates Jean-Pierre Clamadieu, the CEO of Rhodia, commenting on trends in other markets.
A positive pricing-power
Beyond these sustained volumes, the French chemists have now the choice made in the mid-2000s, to reposition their activities, and evolve their product lines towards products "performance" or "specialty" in very high added value.For example, include bioplastics produced by Arkema, to limit the weight of cars and therefore reduce the energy consumption of automobiles. For its part, Rhodia offers silicas for tires also reduces energy consumption, or compounds of high performance detergent products or cosmetics (shampoos, detergents …)
This positioning of substitutable products hardly makes them less sensitive to economic fluctuations, the chemists called "core" whose activity is based on the sale, in very large tonnages, minimally processed materials.
This choice also allows both groups to move more easily to their customers of price increases, a critical factor in a context of rising prices of intermediate raw materials, used in the manufacture of their compounds.This "pricing-power" allows them to maintain profitability, while according to Thierry Hénaff, "the raw materials we use have increased on average by 30% over the first three months of the year and sometimes up to 50 % for some petroleum derivatives quick payday loan.
Rhodia, this rise affected negatively for about 100 million euros on EBITDA (EBITDA). "But our pricing-power has led to a positive 51 million euros on EBITDA" said Jean-Pierre Clamadieu. In the first three months of the year, EBITDA recurring group reached 283 million euros, up 28% (margin of 16.8%), while at Arkema quarterly EBITDA reached 287 million euros. Having more than doubled in one year, it shows a margin of 16.6%.On both sides, net income reached a record 151 million euros.
Faced with these early indications of financial year, the leaders were rather confident for the rest of the year. Arkema Hénaff Thierry should not give targets for the year before summer, but said that the second quarter will be a continuation of the first, with fiscal 2011 "very likely higher than last year already historic for our group. " Rhodia, the annual target of a recurring EBITDA of one billion euros for 2011 was revised to "more than 1 billion euros."
Positive stock market reactions
At the Paris Bourse, investors applauded the figures above expectations. Arkema clinching the title with 4.60% in mid-session (71.8 euros), bringing its increase to 35% since the beginning of the year.Since the IPO just last 5 years (May 18, 2006), the title has been multiplied by more than 2.
For its part, the title being fed Rhodia very logically from 0.16% to 31.53 euros, the title remaining aligned with the price of the friendly takeover announced in April by the Belgian Solvay at a price of 31 60 euros per share. The offer, which should be open in June, would allow both groups, if successful, to form a new group of about 14 billion euros in turnover, for estimated EBITDA of EUR 2 billion .
ALSO READ:
"INTERVIEW:" Arkema ranks among the best "
"Solvay launches takeover bid for Rhodia
A new global giant of chemistry was born
"The chemistry is the head
"Chemistry is ubiquitous and unloved